Full-Time

Global Regulatory Affairs Compliance and Planning Manager

Posted on 6/26/2025

Kyowa Kirin

Kyowa Kirin

1,001-5,000 employees

Global specialty pharma leveraging fermentation and antibodies

Compensation Overview

$135k - $145k/yr

+ Annual Bonus Program + Discretionary Profit Sharing + 401K with company matching + Generous PTO and Holiday Schedule + Healthcare Benefits + HSA & FSA Programs + Well-Being and Work/Life Programs + Long-Term Incentives + Life & Disability Insurance + Concierge Service + Pet Insurance + Tuition Assistance + Employee Referral Awards

Princeton, NJ, USA

Hybrid

Category
Legal & Compliance (2)
,
Required Skills
SAP Products
Risk Management
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • Bachelor’s degree.
  • PMP Certified (PMP) is beneficial but not required.
  • Prior experience in Life sciences industry is beneficial but not required.
  • 7+ years of pharmaceutical experience.
  • Broad understanding of pharmaceutical development, Regulatory Affairs, Quality Assurance, Safety and Commercial.
  • Experience managing cross-functional project teams in a global business environment is required.
  • Experience implementing change management would also be an important experience for this role.
  • Proficient in MS Office Suite (e.g, Microsoft Project, Powerpoint, Excel).
  • Demonstrated ability to organize, prioritize, meet deadlines, make decisions, and change course of action quickly.
  • Strong interpersonal and communication skills.
  • Strong work ethic is required.
  • Excellent problem-solving skills.
  • Detail oriented and excellent follow through.
  • Has the ability to flex and deal with ambiguity in a dynamic, fast-paced, high growth environment.
  • Has a passion for personal learning and development to be able to grow with the company.
  • Cultural sensitivity and ability to develop consensus within a multinational organization.
Responsibilities
  • The Project Manager, Regulatory Affairs Global Compliance and Planning is responsible for driving implementation of and adherence to best practices in project management.
  • This role will be a regional NA lead for Global Compliance and Planning and be responsible for ensuring global compliance and planning initiatives are implemented locally when applicable.
  • The Project Manager will lead or support projects within the Global Compliance and Planning function and other appropriate project management initiatives within RA.
  • This role requires close partnership between global and regional regulatory functions as well as cross functional stakeholders such as QA, PV, and IT.
  • This individual will partner with GRA Compliance and Planning team members to deliver on the strategy of achieving industry leadership, process efficiency, standardization, and ingraining a cultural mindset of continuous improvement.
  • The Project Manager will lead the project planning process and ensure strategic business objectives are met by the most efficient use of budget and resources. This role will be required to think outside the box in developing a strategy and executing on a project effectively.
  • This role will lead GRA risk management tracking initiatives.
  • Support regulatory audits and inspections. Ensure effective processes are in place for tracking CAPAs, deviations.
  • Lead cross functional and regional collaborations to create harmonized processes and SOPs, including conducting a GAP analysis.
  • This individual will develop performance metrics and conduct timely monitoring and reporting of project performance.
  • This role will be responsible for driving excellence in the execution of project role out and maintenance.
Desired Qualifications
  • PMP Certification (PMP) would be beneficial but not required.
  • Prior experience in Life sciences industry is beneficial but not required.

Kyowa Kirin is a global specialty pharmaceutical company that develops medicines using fermentation and antibody technologies. Its products target areas like nephrology, oncology, and immunology, with therapies built from biologics and other drug modalities. The company emerged from a merger between Kyowa Hakko Kogyo and Kirin Pharma, combining Kyowa’s fermentation and microbiology expertise with Kirin’s pharma resources to create a worldwide focus on specialty drugs. Unlike broader drug companies, Kyowa Kirin concentrates on a defined set of indications and runs a research-and-development-led business that aims to deliver innovative treatments for patients in need.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1885

Simplify Jobs

Simplify's Take

What believers are saying

  • Libmeldy commercialization in MLD expands rare disease revenue streams globally.
  • Orchard pipeline programs in MPS, FTD, Crohn's disease address high unmet needs.
  • North Carolina manufacturing capacity supports cell and gene therapy market growth.

What critics are saying

  • Libmeldy reimbursement denial in UK, Germany, US collapses primary revenue driver.
  • Orchard pipeline failures in Phase 2/3 trials eliminate $478M acquisition rationale.
  • Gene therapy manufacturing delays at Sanford facility constrain supply and revenue ramp.

What makes Kyowa Kirin unique

  • 75+ years fermentation expertise underpins proprietary antibody and gene therapy platforms.
  • Orchard Therapeutics acquisition adds Libmeldy gene therapy for rare genetic diseases.
  • $530M Sanford biologics facility enables scaled manufacturing of advanced cell therapies.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Kyowa Kirin who can refer or advise you

Benefits

401(k) Company Match

Paid Vacation

Paid Sick Leave

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Hybrid Work Options

Pet Insurance

Tuition Assistance

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-1%
Benzinga
Dec 15th, 2025
Link Cell Therapies raises $92M to advance CAR-T cancer treatments for solid and liquid tumors

Link Cell Therapies has emerged from stealth with $60 million in Series A funding led by Johnson & Johnson Innovation – JJDC, bringing total capital raised to $92 million. The South San Francisco–based oncology company is developing CAR-T therapies for solid and liquid tumours using proprietary logic-gating technology. The platform enables safe targeting of multiple antigens co-expressed on cancer cells whilst sparing healthy tissue. Co-founded by Dr Robbie Majzner and Dr Crystal Mackall at Stanford University in 2022, Link's lead programme, LNK001 for renal cell carcinoma, is on track for an IND application and Phase I trial in 2026. The Series A round included participation from founding investors Samsara BioCapital and Sheatree Capital, alongside new backers Bristol Myers Squibb, Kyowa Kirin and Wing Venture Capital.

FinSMEs
Mar 4th, 2025
Garuda Therapeutics Closes $50M Series A-1 Financing

Garuda Therapeutics, a Cambridge, MA-based hematopoietic stem cell (HSC) therapies company, raised $50M in Series A-1 funding

Cimeio Therapeutics
Dec 10th, 2024
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies

The partnership combines Cimeio's proprietary Shielded Cell and Immunotherapy (SCIP) platform with Kyowa Kirin's expertise in cellular therapies and underscores both companies' commitment to using emerging cell and gene therapy technologies to develop new ways to treat patients.

Business North Carolina
Nov 27th, 2024
Op/ed: Biotech's role in North Carolina's job-creation success

Kyowa Kirin, a Japanese global specialty pharmaceutical company, plans to invest more than $200 million in Sanford to build its first pharmaceutical manufacturing complex in North America, adding more than 100 new jobs.

World Pharmaceutical Frontiers
Jun 11th, 2024
Kyowa Kirin to establish new $530m biologics manufacturing plant in US

Japan-based Kyowa Kirin has unveiled its plans to invest $530m to build a new advanced biologics manufacturing facility in Sanford in the American state of North Carolina.

INACTIVE